Article
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Skin Lesions in Patients Treated With Imatinib Mesylate: A 5-Year Prospective Study
- Author:
- Giovanni Paolino, MD
- Dario Didona, MD
- Rita Clerico, MD
- Paola Corsetti, MD
- Marina Ambrifi, MD
- Ugo Bottoni, PhD
- Stefano Calvieri, PhD
Imatinib mesylate (IM) represents the first-line treatment of patients with chronic myeloid leukemia (CLM) or gastrointestinal stromal tumor (GIST...